Advarra—which provides institutional review board (IRB), institutional biosafety committee, research technology solutions, and quality/compliance consulting services—has purchased IRB Company (IRBco). IRBco is an AAHRPP-accredited central IRB in operation since 1981.
According to Gadi Saarony, Advarra CEO, the acquisition will enable his company to further its mission to empower clinical trials to do their work, and to advance human health.
“IRBco studies will be fully integrated with Advarra in a matter of weeks, and we look forward to the additional talent and board expertise this will bring to our organization,” he said. “We will maintain our focus on developing altogether better capabilities that serve clients and protect research participants.”
Advarra offers a range of products and services designed to streamline processes, create efficiencies, and support research compliance. These capabilities are intended to provide the research and biopharmaceutical industries with integrated solutions.
According to Advarra, the acquisition will increase its reach to more than 3,200 research institutions, hospital systems, and academic medical centers.
Anil Sharma, CEO of IRBco, said joining forces makes sense for both companies, and their clients.
“Joining the Advarra family is an ideal fit,” he said. “We are pleased to offer our mutual customers expanded resources—innovations, efficiencies, and all the characteristics to collaboratively complement moving research forward.”
Overall, Advarra offers technology products and consulting services that are geared toward accelerating research through technologies, strategic partnerships, and customer-centric service. According to the company, the approach reduces operational costs, streamlines study startup activities, prevents errors and administrative burdens, and saves time for clinical research sponsors, CROs, investigators, and institutions.
